Cette traduction est en cours de préparation. En attendant, nous affichons temporairement la version originale en anglais.
Entreprise · 12/07/20221 min de lecture
Revocation of Emergency Use of a Drug During the COVID-19 Pandemic; Availability
Traduction automatique locale · Langue originale de la source
Résumé
The Food and Drug Administration (FDA) is announcing the revocation of the Emergency Use Authorization (EUA) (the Authorization) issued to Fresenius Kabi USA, LLC (Fresenius Kabi), for Fresenius Propoven 2% Emulsion. FDA revoked the Authorization on May 10, 2022, under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The revocation, which includes an explanation of the reasons for the revocation, is reprinted in this document.
Langue originale de la source: Federal Register — Food and Drug AdministrationOuvrir le communiqué original →